Literature DB >> 19640210

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.

Véronique Rabenda1, Michaël Hiligsmann, Jean-Yves Reginster.   

Abstract

Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic women are poor. Although extending dosing intervals improved adherence, the gains are suboptimal. Most importantly, low compliance and persistence rates consistently resulted in increased rates of fractures. The results emphasize the importance of adherence to treatment to achieve optimal antifracture efficacy. There is an urgent need to implement strategies and to encourage physicians to take measures that increase patients' awareness of the need to use osteoporosis medications as directed in order to benefit from them fully.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640210     DOI: 10.1517/14656560903140533

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  32 in total

1.  Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

Authors:  S M Cadarette; D H Solomon; J N Katz; A R Patrick; M A Brookhart
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations.

Authors:  Milica Nikitovic; Daniel H Solomon; Suzanne M Cadarette
Journal:  Ther Adv Chronic Dis       Date:  2010-11-01       Impact factor: 5.091

3.  Denosumab.

Authors:  René Rizzoli; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 4.  Measuring and improving adherence to osteoporosis pharmacotherapy.

Authors:  Suzanne M Cadarette; Andrea M Burden
Journal:  Curr Opin Rheumatol       Date:  2010-07       Impact factor: 5.006

5.  Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule.

Authors:  D H Solomon; M A Brookhart; P Tsao; D Sundaresan; S E Andrade; K Mazor; R Yood
Journal:  Osteoporos Int       Date:  2010-09-29       Impact factor: 4.507

Review 6.  Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.

Authors:  M Hiligsmann; M Salas; D A Hughes; E Manias; F H Gwadry-Sridhar; P Linck; W Cowell
Journal:  Osteoporos Int       Date:  2013-05-01       Impact factor: 4.507

7.  Fractures and mortality in relation to different osteoporosis treatments.

Authors:  Huifeng Yun; Elizabeth Delzell; Kenneth G Saag; Meredith L Kilgore; Michael A Morrisey; Paul Muntner; Robert Matthews; Lingli Guo; Nicole Wright; Wilson Smith; Cathleen Colón-Emeric; Christopher M O'Connor; Kenneth W Lyles; Jeffrey R Curtis
Journal:  Clin Exp Rheumatol       Date:  2014-07-28       Impact factor: 4.473

8.  A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years.

Authors:  M Audran; F J Jakob; S Palacios; M-L Brandi; H Bröll; N A T Hamdy; E V McCloskey
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

9.  Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2010-04-26       Impact factor: 2.423

10.  Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008.

Authors:  B McGowan; K Bennett; M C Casey; J Doherty; C Silke; B Whelan
Journal:  Ir J Med Sci       Date:  2013-03-13       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.